

## Data regarding PSA variation following the use of the Peenuts® Formula at varying intervals

INITIALS	PSA	F/U PSA	% CHANGE	TIME TO SURVEILLANCE	COMMENTS
S.S.	16.6	11.3	32%	37 mo.	Biopsy Negative x 2
M.S	14.9	6.7	55%	6 mo.	Biopsy Negative
D.J.	33.9	5.7	83%	6 mo.	Biopsy Negative
D.L.	5.6	1.8	68%	14 mo.	HGPIN
D.S.	7	2.6	63%	14 mo.	HGPIN (Biopsy x 3)
B.L.	5.8	4.9	16%	1 mo.	PC
R.L.	5.3	4.9	8%	4 mo.	PC
S.K.	4.2	1.6	62%	12 mo.	PC
R.P.	8.4	2.9	65%	13 mo.	PC
F.W.	8.5	3.1	64%	72 mo.	PC; + Avodart®
J.B.	7	2.4	66%	60 mo.	PC
S.A.	4.7	2.1	55%	41 mo.	PC; + Avodart®
J.W.	11.7	5.8	50%	60 mo.	PC
R.C.	2.9	1.7	41%	72 mo.	PC
J.C.	2.1	2.8	33%(+)	42 mo.	PC; + Avodart®
W.G.	7.3	4.5	38%	40 mo.	PC; + Avodart®
R.V.	6.9	6	13%	38 mo.	PC
D.S.	9.1	5.5	40%	58 mo.	PC
J.G.	3.2	2	38%	21 mo.	PC; + Avodart®
G.D.	6.2	4.4	29%	21 mo.	PC
C.B.	4.4	1.7	61%	39 mo.	PC; + Avodart®
J.S.	11.4	12.3	8%(+)	34 mo.	PC

INITIALS	PSA	F/U PSA	% CHANGE	TIME TO SURVEILLANCE	COMMENTS
L.R.	6.8	1.9	72%	49 mo.	PC; + Avodart®
E.E.	6.6	1.8	73%	24 mo.	PC
J.M.	14.4	1.5	90%	29 mo.	PC; + Avodart®
J.C.	8.4	1.8	79%	18 mo.	PC; + Avodart®
R.W.	4.4	4.7	7%(+)	14 mo.	PC; + Avodart®
R.C.	6.1	1.3	79%	13 mo.	PC
R.W.	0.5	0.3	40%	84 mo.	
A.C.	3.6	1.4	61%	4.5 mo.	
B.R.	1.2	0.58	52%	6 mo.	
R.A.	0.9	0.7	22%	6 mo.	
C.B.	6.9	5.8	16%	6 mo.	
L.A.	3.4	2.7	21%	6 mo.	
P.R.	3.9	3	23%	6 mo.	
B.D.	9.26	8.44	9%	3 mo.	
R.C.	7	4.6	34%	19 mo.	
N.F.	6.8	2.5	63%	16 mo.	
S.G.	3.5	2.6	26%	12 mo.	
R.G.	4.4	4.9	11%(+)	9 mo.	
R.H.	9.1	3.36	63%	27 mo.	
G.H.	13	9.6	26%	2 mo.	
F.H.	6.5	3.9	40%	12 mo.	
S.H.	1.16	0.92	21%	12 mo.	
R.H.	13	11.4	12%	7 mo.	
D.H.	5.8	4.7	19%	2 mo.	
D.J.	13.8	5.23	62%	4 mo.	
D.G.	3.3	0.97	71%	26 mo.	
E.L.	7.6	4.3	43%	47 mo.	
B.M.	0.6	0.4	33%	41 mo.	
K.M.	4.8	1.9	60%	15 mo.	
J.M.	11.79	6.7	43%	24 mo.	
E.M.	10.6	8.8	17%	8 mo.	
W.M.	0.7	0.7	0%	25 mo.	
W.M.	3.8	2	47%	48 mo.	
R.M.	6.3	4.4	30%	22 mo.	
C.M.	3.7	1.6	57%	24 mo.	
R.M.	6.6	3.2	46%	39 mo.	
R.S.	1.64	0.9	45%	4 mo.	

INITIALS	PSA	F/U PSA	% CHANGE	TIME TO SURVEILLANCE	COMMENTS
R.N.	2.89	1.77	39%	7 mo.	
R.N.	5.8	2.43	58%	32 mo.	
FR.	10.8	5.2	52%	6 mo.	
J.R.	9.84	4.3	56%	12 mo.	
FR.	5.2	3.1	40%	6 mo.	
J.R.	7.1	2.8	61%	44 mo.	
WS.	2.4	1.6	33%	56 mo.	
DS.	11.7	3.7	68%	19 mo.	
M.W.	7.1	5.6	21%	8 mo.	
T.M.	7.7	3.8	51%	48 mo.	<b>Biopsy Negative</b>
S.G.	0.6	0.6	0%	42 mo.	
J.K.	5.4	2.6	48%	48 mo.	
DS.	9.8	3.7	62%	15 mo.	<b>Plus Avodart®</b>
RE.	24.1	9.2	62%	9 mo.	<b>Bx.X(2)(Neg); Plus Avodart®</b>
L.W.	6.4	0.7	89%	> 6 mo.	
T.G.	43	7.4	83%	4 mo.	
R.D.	16	3.8	76%	11 mo.	
R.V.	2.9	2.1	28%	> 6 mo.	
B.C.	2.1	0.9	57%	> 6 mo.	
B.M.	7.9	7	11%	> 6 mo.	
H.M.	11.4	4.1	64%	10 mo.	
C.A.	14	2.7	81%	> 6 mo.	
J.S.	8.4	4.2	50%	8 mo.	
M.S.	3.8	0.8	79%	> 6 mo.	
R.V.	25	16	36%	9 mo.	<b>Biopsy Negative X 2</b>
G.S.	6.8	4.7	31%	> 6 mo.	
G.M.	8.8	5.4	39%	> 6 mo.	
DE.	25.3	3	88%	8 mo.	<b>Biopsy Negative</b>
CR.	4.7	3.7	21%	> 6 mo.	
B.G.	2.5	2.1	16%	> 6 mo.	
C.P.	4.1	2.8	32%	> 6 mo.	
V.J.	4.5	3.6	20%	> 6 mo.	
L.V.	15.6	5.4	65%	> 6 mo.	
D.V.	3.8	1.2	68%	> 6 mo.	
J.C.	10	3.1	69%	> 6 mo.	
C.C.	22	19	14%	> 6 mo.	

<b>INITIALS</b>	<b>PSA</b>	<b>F/U PSA</b>	<b>% CHANGE</b>	<b>TIME TO SURVEILLANCE</b>	<b>COMMENTS</b>
<b>H.F.</b>	5.3	4.6	13%	> 6 mo.	
<b>F.J.</b>	7.5	5.2	31%	> 6 mo.	
<b>R.H.</b>	8.5	5.4	37%	> 6 mo.	
<b>R.A.</b>	2.5	2.2	12%	> 6 mo.	
<b>R.G.</b>	5.9	5.5	7%	> 6 mo.	
<b>G.T.</b>	1.4	0.8	43%	6 mo.	
<b>G.H.</b>	36	1.6	96%	> 6 mo.	
<b>V.S.</b>	3.8	2.9	24%	> 6 mo.	
<b>C.C.</b>	5.6	4.3	23%	> 6 mo.	
<b>R.L.</b>	7.4	4.1	45%	> 6 mo.	
<b>C.D.</b>	3.6	2.4	33%	> 6 mo.	
<b>J.L.</b>	4.0	3.5	13%	4 mo.	
<b>L.G.</b>	1.3	0.9	31%	12 mo.	
<b>R.S.</b>	11.0	5.8	47%	4 mo.	
<b>E.L.</b>	6.7	4.2	37%	3.5 mo.	
<b>M.L.</b>	11.4	7.4	35%	3 mo.	
<b>C.T.</b>	2.6	2.0	23%	5 mo.	
<b>L.S.</b>	4.1	3.4	17%	10 mo.	
<b>E.S.</b>	4.3	3.2	26%	6 mo.	
<b>J.B.</b>	4.6	3.9	15%	9 mo.	
<b>B.D.</b>	9.3	4.8	48%	5 mo.	
<b>M.S.</b>	7.5	5.4	28%	9 mo.	
<b>R.N.</b>	7.0	2.1	69%	8 mo.	
<b>E.G.</b>	4.7	4.1	13%	3 mo.	
<b>L.L.</b>	2.6	1.3	50%	13 mo.	
<b>D.L.</b>	18.0	10.5	42%	4 mo.	<b>Negative Biopsy X 2</b>
<b>H.K.</b>	5.6	2.6	54%	6 mo.	
<b>P.H.</b>	1.0	0.9	10%	6 mo.	
<b>A.A.</b>	4.5	0.8	82%	9 mo.	
<b>C.C.</b>	5.9	3.7	37%	14 mo.	
<b>J.A.</b>	7.5	4.9	35%	2 mo.	
<b>R.A.</b>	0.8	0.5	38%	10 mo.	
<b>E.H.</b>	0.9	0.6	33%	20 mo.	
<b>R.D.</b>	13.6	7.2	47%	2 mo.	
<b>E.H.</b>	1.5	1.2	20%	12 mo.	
<b>T.M.</b>	8.1	1.7	79%	2 mo.	
<b>R.K.</b>	25	16	36%	> 6 mo.	

INITIALS	PSA	F/U PSA	% CHANGE	TIME TO SURVEILLANCE	COMMENTS
L.T.	6.8	4.7	31%	> 6 mo.	
A.B.	8.8	5.4	39%	> 6 mo.	
D.M.	3.8	0.8	79%	> 6 mo.	
A.S.	2.9	2.1	28%	> 6 mo.	
L.M.	8.4	4.2	50%	> 6 mo.	
C.B.	14	2.7	81%	> 6 mo.	
K.T.	11.4	4.1	64%	> 6 mo.	
S.R.	7.9	7.0	11%	> 6 mo.	
I.B.	25.3	3.0	88%	> 6 mo.	
S.W.	4.7	3.7	21%	> 6 mo.	
C.F.	2.5	2.1	16%	> 6 mo.	
E.C.	4.5	3.6	20%	> 6 mo.	
B.R.	4.1	2.8	32%	> 6 mo.	
S.H.	15.6	5.4	65%	> 6 mo.	
R.R.	3.8	1.2	68%	> 6 mo.	
T.S.	10	3.1	69%	> 6 mo.	
J.D.	22	19	14%	> 6 mo.	
C.L.	5.3	4.6	13%	> 6 mo.	
A.L.	7.5	5.2	31%	> 6 mo.	
A.R.	8.5	5.4	37%	> 6 mo.	
M.M.	2.5	2.2	12%	> 6 mo.	
N.S.	5.9	5.5	7%	> 6 mo.	
<b>N=154</b>	<b>Mean 7.8</b>	<b>Mean 3.9</b>	<b>50%</b>		